2480 — Beijing Luzhu Biotechnology Co Income Statement
0.000.00%
Last trade - 00:00- HK$4.61bn
- HK$4.44bn
Annual income statement for Beijing Luzhu Biotechnology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 530 | 721 | 248 | 167 | 144 |
| Operating Profit | -530 | -721 | -248 | -167 | -144 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -539 | -725 | -249 | -168 | -150 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -539 | -725 | -249 | -168 | -150 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -539 | -725 | -249 | -168 | -150 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -539 | -725 | -249 | -168 | -150 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.65 | -3.48 | -1.12 | -0.832 | -0.723 |